Dulaglutide vs Survodutide
A side-by-side research comparison of Dulaglutide and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dulaglutide | Survodutide |
|---|---|---|
| Full name | Dulaglutide (Trulicity) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Prescription medication (FDA-approved) | Phase 3 Clinical Trial |
| Mechanism | Activates GLP-1 receptors in pancreatic beta cells (enhancing glucose-dependent insulin secretion), the hypothalamus (reducing appetite), and the GI tract (slowing gastric emptying). The Fc fusion extends half-life to ~5 days. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | ~63,000 Da | 4,500 Da (approximate) |
| Half-life | ~5 days (supports weekly dosing) | 5-7 days |
| Bioavailability | ~65% subcutaneous | High (SubQ) |
| Typical dose | 0.75 mg - 4.5 mg once weekly | 0.6-6.0 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous injection (pre-filled pen) | Subcutaneous |
Dulaglutide reported benefits
- Significant weight loss (3-5% at standard doses)
- Improved glycemic control
- Reduced cardiovascular events (REWIND trial)
- Once-weekly convenience
- Appetite suppression
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.